PURPOSE: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis. MATERIALS AND METHODS: Proteins from human lung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. RESULTS: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis. CONCLUSION: Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.
PURPOSE: We have implemented a high throughput platform for quantitative analysis of serum autoantibodies, which we have applied to lung cancer for discovery of novel antigens and for validation in prediagnostic sera of autoantibodies to antigens previously defined based on analysis of sera collected at the time of diagnosis. MATERIALS AND METHODS: Proteins from humanlung adenocarcinoma cell line A549 lysates were subjected to extensive fractionation. The resulting 1,824 fractions were spotted in duplicate on nitrocellulose-coated slides. The microarrays produced were used in a blinded validation study to determine whether annexin I, PGP9.5, and 14-3-3 theta antigens previously found to be targets of autoantibodies in newly diagnosed patients with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage and to determine whether additional antigens may be identified in prediagnostic sera. Individual sera collected from 85 patients within 1 year before a diagnosis of lung cancer and 85 matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were hybridized to individual microarrays. RESULTS: We present evidence for the occurrence in lung cancer sera of autoantibodies to annexin I, 14-3-3 theta, and a novel lung cancer antigen, LAMR1, which precede onset of symptoms and diagnosis. CONCLUSION: Our findings suggest potential utility of an approach to diagnosis of lung cancer before onset of symptoms that includes screening for autoantibodies to defined antigens.
Authors: S Butò; E Tagliabue; E Ardini; A Magnifico; C Ghirelli; F van den Brûle; V Castronovo; M I Colnaghi; M E Sobel; S Ménard Journal: J Cell Biochem Date: 1998-06-01 Impact factor: 4.429
Authors: Lorenz Höltl; Claudia Zelle-Rieser; Hubert Gander; Christine Papesh; Reinhold Ramoner; Georg Bartsch; Hermann Rogatsch; Adel L Barsoum; Joseph H Coggin; Martin Thurnher Journal: Clin Cancer Res Date: 2002-11 Impact factor: 12.531
Authors: E Ardini; G Pesole; E Tagliabue; A Magnifico; V Castronovo; M E Sobel; M I Colnaghi; S Ménard Journal: Mol Biol Evol Date: 1998-08 Impact factor: 16.240
Authors: V Cioce; V Castronovo; B M Shmookler; S Garbisa; W F Grigioni; L A Liotta; M E Sobel Journal: J Natl Cancer Inst Date: 1991-01-02 Impact factor: 13.506
Authors: E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old Journal: J Exp Med Date: 1998-04-20 Impact factor: 14.307
Authors: Liping Dai; Jitian Li; Jun-Chieh J Tsay; Ting-An Yie; John S Munger; Harvey Pass; William N Rom; Eng M Tan; Jian-Ying Zhang Journal: Oncoimmunology Date: 2017-03-31 Impact factor: 8.110
Authors: Pavel Gromov; Irina Gromova; Jakob Bunkenborg; Teresa Cabezon; José M A Moreira; Vera Timmermans-Wielenga; Peter Roepstorff; Fritz Rank; Julio E Celis Journal: Mol Oncol Date: 2009-11-23 Impact factor: 6.603
Authors: William N Rom; Judith D Goldberg; Doreen Addrizzo-Harris; Heather N Watson; Michael Khilkin; Alissa K Greenberg; David P Naidich; Bernard Crawford; Ellen Eylers; Daorong Liu; Eng M Tan Journal: BMC Cancer Date: 2010-05-26 Impact factor: 4.430